Unlocking the Potential of Pro10™ Cells: A Revolutionary Mammalian Suspension Technology for Scalable Recombinant Adeno-Associated Virus Production in Gene Therapy

A Pro10 Cell Line: Proprietary Mammalian Suspension Technology for Scalable rAAV Production

The Pro10™ cell line is a new technology that improves the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. This proprietary mammalian suspension technology has been developed to address the challenges associated with large-scale manufacturing in AAV gene therapies.

Viralgen utilizes the Pro10™ cells as the core of a reliable and scalable rAAV vector manufacturing process. These cells have been optimized specifically for rAAV production and have successfully been scaled up to 2000L, achieving consistent and reproducible cell growth rates. They are capable of producing various AAV serotypes and have demonstrated productivity levels similar to both small and large-scale bioreactors.

The Pro10™ cells play a critical role in Viralgen’s platform process for manufacturing AAV vectors and have contributed significantly to the production of innovative gene therapies. For more information on this HEK293 derived animal component-free suspension Pro10™ cell line, please access the full PDF detailing its properties and potential benefits for process development in gene therapy.

Leave a Reply